Marker Therapeutics Narrows Q1 Net Loss by 28%, Extends Cash Runway to Q1 2027
MRKR sits 80% above its 52-week low of $0.81 on light trading volume (0.2× avg).
Summary
Marker Therapeutics reported a Q1 2026 net loss of $(3.18M) and diluted EPS of $(0.16), representing a 28% year-over-year reduction in net loss. This improvement was partly driven by a significant increase in non-dilutive grant income, which more than doubled to $751,691. Critically, the company now expects its cash runway to extend into Q1 2027, an important update given the previous 10-K's going concern warning and short cash runway. While still operating at a loss, the improved financial performance and extended liquidity provide a more stable near-term outlook for this micro-cap biotech. Investors will closely watch for further updates on additional equity and grant funding, as well as progress on its clinical pipeline, including the planned pivotal lymphoma trial in 2026.
At the time of this announcement, MRKR was trading at $1.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.7M. The 52-week trading range was $0.81 to $4.07. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.